< BACK

VANCOUVER, B.C., CANADA (February 21, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”) President and CEO, Mr. Gary Thompson, announces that Mr. William A. Rodgers Jr., of Milton, Georgia has been appointed to the Company’s board of directors.

“As M Pharma continues to expand its product portfolio, advance regulatory processes and prepare for marketplace launches, adding the vast experience that William Rodgers brings to our board of directors strengthens the Company significantly,” said Mr. Gary Thompson, President and CEO.

Mr. Rodgers holds a B.S. in Accounting, having worked early in his career in public accounting and having held senior executive positions at Fortune 150 Corporations including Waste Management, Inc. and Johnson Controls, Inc. More recently Rodgers served as President and Chief Executive Officer for EMCOR Facilities Services, Inc. and GoodCents Holdings, Inc.

“Bill’s strong and significant senior executive leadership strengths will serve M Pharma in multiple ways, including financial analysis, acquisition and start up activities, new market entry analysis and strategic planning. His experience in developing proactive marketing strategies will be integral to our success going forward,” noted Gary Thompson. “We are excited to welcome Bill to the team, and we look forward to further additions to our Board as we prepare to market the Company’s strong portfolio of drugs and treatments within the obesity and women’s health space,” added Mr. Thompson.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity and weight management.  In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the Company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.  The Company has also recently acquired an FDA cleared fertility product branded as ToConceive that represents its first offering in the women’s health field.

M Pharma trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:
Investor Relations
Phone: +1 604 428 0511
info@m-pharma.ca
www.m-pharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103 and Trimeo are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

ABOUT CALLITAS

As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.

INVESTOR INQUIRIES

  • 1.859.868.3131
  • investors@callitas.com

  • 187 Pavilion Parkway
    Suite 200
    Newport, Kentucky 41071

PRESS AND MEDIA INQUIRIES

  • pressroom@callitas.com

PRODUCT INQUIRIES